Article Detail - JF Part B
MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease - Effective December 06, 2020
This Local Coverage Determination (LCD) has completed the Open Public Meeting and comment period and is now finalized under contractor numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY). Responses to comments received may be found as a link at the bottom of the final LCD.
Medicare Coverage Database (MCD) Number/Contractor Determination Number: L38341
LCD Title: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease
FORMERLY: MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with Favorable Intermediate Risk Disease
Effective Date: December 06, 2020
Summary of LCD: Limited coverage policy for genomic derived tests that assess risk in localized (non-metastatic) prostate cancer. The review is focused on the Decipher® Prostate Cancer Classifier Assay. The test is considered reasonable and necessary to help identify men with localized prostate cancer and a life expectancy of at least 10 years who are good candidates for active surveillance according to the most recent National Comprehensive Cancer Network (NCCN) guidelines.
Visit the Future LCDs webpage to access this LCD.
Last Updated Thu, 22 Oct 2020 18:09:16 +0000